Zobrazeno 1 - 5
of 5
pro vyhledávání: '"K A Lytkina"'
Autor:
Dmitry Evgenyevich Karateev, E L Nasonov, L N Denisov, M L Stanislav, E Yu Panasyuk, I A Andrianova, V I Mazurov, E S Zhugrova, Yu P Uspensky, L N Belousova, E P Ilivanova, G K Matsiyevskaya, G P Aurtyunov, K A Lytkina, R S Saikovsky, V N Ardashev, E V Zhilyaev, N I Korshunov
Publikováno v:
Научно-практическая ревматология, Vol 50, Iss 2, Pp 14-19 (2012)
Certolizumab pegol (CZP) is a new drug from the group of tumor necrosis factor a inhibitors. The efficacy and safety CZP in the treatment of rheumatoid arthritis (RA) have been studied in the international 52-week RAPID-1 and 24-week RAPID-2 clinical
Externí odkaz:
https://doaj.org/article/101a52e2f0e349c78a5f2b4e52dc7d4f
Publikováno v:
Современная ревматология, Vol 0, Iss 2, Pp 67-68 (2008)
Tsel' issledovaniya. Otsenivali vliyanie korotkogo kursa terapii movalisom na kachestvo zhizni patsientov s osteoartrozom. Materialy i metody. Dlya opredeleniya kachestva zhizni bol'nykh ispol'zovalsya obshchiy oprosnik EQ-5D. V techenie 10 dney pats
Externí odkaz:
https://doaj.org/article/43c32ffb547d4b92a43e9a8fa8a48753
Publikováno v:
Modern Rheumatology Journal. 16:26-31
Currently, a large number of highly effective biologic disease modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) are used for the treatment of rheumatoid arthritis (RA). However, in addition to effectiveness, it is nece
Autor:
S. V. Topolyanskaya, T. A. Eliseeva, O. I. Turna, O. N. Vakulenko, M. A. Romanova, L. I. Dvoretski, S. A. Rachina, K. A. Lytkina, G. G. Melkonyan
Publikováno v:
Medical alphabet. :19-25
Aim: to study the features of purine, lipid and carbohydrate metabolic disorders in patients with coronary artery disease over 90 years old (centenarians).Materials and methods. The study enrolled 225 patients over 90 years, hospitalized with coronar
Autor:
I. Yu. Murashova, K. V. Lytkina
Publikováno v:
Pedagogical IMAGE. 13:138-145